근침윤성 방광암 환자의 방광 보존적 치료 결과 = Bladder Preserving Treatment in Patients with Muscle Invasive Bladder Cancer

국문 초록 (Abstract)

목 적: 근침윤성 방광암으로 진단받고 방광 보존적 치료를 시행받은 환자를 대상으로 종양 반응 정도 및 생존율을
분석하고 이에 영향을 주는 예후 인자를 알아보고자 하였다. 대상 및 방법: 1995년 9월부터 2004년 6월까지 삼성서울병원에서 방광암으로 진단 받고 방광 보존적 치료를 받은 환자 39명 중 편평상피암 환자 1명과 선암 환자 1명을 제외한 37명의 환자를 후향적으로 분석하였다. 성별로는 남녀가 각각 33명, 4명이었으며 연령은 38∼86세(중앙값 67세)였다. 조직학적으로 모두 이행상피암이었다. 임상적으로 원발 병소 병기는 T2, T3, T4가 각각 19명, 13명, 5명이었다. 경요도방광절제술(TURB) 시 완전 절제와 부분절제가 각각 17명과 19명에서 시행되었고, 조직 검사만 시행된 경우가 1명 있었다. 항암화학방사선병용요법을 받은 환자가 24명, 유도 항암화학요법 후 방사선 치료를 받은 환자가 8명, 방사선 치료만 받은 환자가 6명이었고 보조항암화학요법을 시행받은 환자가 18명이었다. 방사선 치료는 10∼15 MV 광자선을 사용하였으며 하루에 1.8∼2.0 Gy로 전골반을 대상으로 45∼46 Gy를 4문 조사한 후 방광에만 국한하여 3차원 입체조형치료로 10.8∼22.0
Gy (중앙값 19.8 Gy) 추가하여 총 55.8∼67 Gy (중앙값 64.8 Gy)를 조사하였다. 항암화학치료는 Cisplatin을 기본
으로 하여 2∼6회(중앙값 3회) 시행하였다. 각 변수 간의 상관 관계 분석은 Chi-Square test를 이용하였다. 생존율
은 Kaplan-Meier 법으로 산출하였고 두 군 간의 비교는 Log-rank test 이용하였다. 생존율에 영향을 미치는 요인들
의 다변량 분석은 Cox 비례위험 모델을 이용하였다. 유의수준 0.05 미만을 의미있는 것으로 판단하였다. 결 과: 치료 반응 평가는 치료 종료 후 3개월 전후에 시행한 요세포 검사, 방광 내시경 소견 및 복부골반 전산화단층촬영을 종합하여 판단하였는데, 완전 관해, 비완전 관해가 각각 16명(43%), 20명(54%)이었다. 대상 환자의 3년전체 생존율은 54.7%였고 중앙 생존 기간은 54개월(3∼91개월)이었다. 3년 무진행 생존율은 37.2%였다. 추적 관찰 중 24명(64.9%)이 재발하였는데 국소 재발이 17명(46%), 원격 전이가 6명(16%), 국소 재발과 원격 전이가 동시에 나타난 경우가 1명(3%) 있었다. 국소 재발의 구제 요법으로 근치적 방광절제술이 시행된 경우는 없었고 TURB만 시행하거나 항암화학치료가 병행되기도 하였다. 치료 후의 반응 정도가 전체 생존율(p=0.006)과 무진행 생존율(p=0.001)에 통계적으로 의미있는 인자였고, TURB의 정도가 전체 생존율(p=0.091)과 무진행 생존율(p=0.081), 방사선 조사선량이 무진행 생존율(p=0.07)에서 통계적 의의에 접근하였다. 결 론: 방광 보존적 치료 시 치료 후 반응 정도가 전체 생존율과 무진행 생존율에 있어 중요한 예후 인자임을 알 수 있었다. 또한, TURB를 가능한 충분히 시행하고 병소 부위에 방사선 조사선량을 높이는 것이 방광보존 치료에서중요하리라 생각된다. 그리고, 방광보존 치료 후 치료 반응 판정에서 완전 관해가 오지 않은 경우는 수술 등의 적극
적인 구제 치료가 필요하겠다. 향후 방광 보존을 위한 항암화학 방사선 병용치료 프로토콜에 따른 임상 경험을 더
쌓아야 할 것으로 생각된다.

다국어 초록 (Multilingual Abstract)

Purpose: This study analyzed the tumor response, overall survival, progression free survival and related prognostic factors in patients with muscle invasive bladder cancer subjected to bladder preserving treatment.
Materials and Methods: Between August 1995 and June 2004, 37 patients with muscle invasive (transitional cell
carcinoma, clinically stage T2-4) bladder cancer were enrolled for the treatment protocol of bladder preservation. There were 33 males and 4 females, and the median age was 67 years (range 38∼86 years).
Transurethral resection of the bladder (TURB) was performed in 17 patients who underwent complete resection.
The median radiation dose administered was 64.8 Gy (range 55.8∼67 Gy). The survival rate was calculated by
the Kaplan-Meier method. Results: An evaluation of the response rate was determined by abdomen-pelvic CT and cystoscopy at three months after radiotherapy. A complete response was seen in 17 patients (46%). The survival rate at three years was 54.7%, with 54 months of median survival (range 3∼91 months). During the study, 17 patients died and 13 patients had died from bladder cancer. The progression free survival rate at three years was 37.2%. There were 24 patients (64.9%) who had disease recurrence: 16 patients (43.2%) had local recurrence, 6 patients (16.2%) had a distant recurrence, and 2 patients (5.4%) had both a local and distant recurrence. The survival rate (p=0.0009) and progression free survival rates (p=0.001) were statistically significant when compared to the response rate after radiotherapy. Conclusion: The availability of complete TURB and appropriate chemoradiotherapy were important predictors for bladder preservation and survival.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 고안 및 결론

참고문헌 (Reference)

1 Shipley WU, "Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery" 931-935, jama1987;258

2 Shipley WU, "The selection of patients for treatment by full-dose irradiation" 2278-2284,

3 Lehmann J, "The role of adjuvant chemotherapy for muscle invasive bladder cancer" 19 : 133-140, 2001

4 Morrison R, "The results of treatment of cancer of the bladder-a clinical contribution to radiobiology" 67-75, clinradiol1975;26

5 Duncan W, "The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy" 299-310, radiotheroncol1986;7

6 Pollack A, "The relationship of local control to distant metastasis in muscle invasive bladder cancer" 154 : 2059-2063, 1995

7 Chung WK, "The prognostic factors affecting survival in muscle invasive bladder cancer treated with radiotherapy" 20 : 130-138, 2002

8 Kim HL, "The current status of bladder preservation in the treatment of muscle invasive bladder cancer" 164 : 627-632, 2000

9 Jacobsen AB, "T2/T3 bladder carcinomas treated with definitive radiotherapy with emphasis on flow cytometric DNA ploidy values 923-929Bladder Preserving Treatment in Patients withMuscle Invasive Bladder CancerJeong Il Yu"

10 Cheon J, "Survey of incidence of urological cancer in South Korea: a 15-year summary" 9 : 445-454, 2002

11 Birkenhake S, "Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer" 174 : 121-127, 1998

12 Hawkins NV, "Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder" 1448-1453, jurol1989;142

13 Stein JP, "Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients" 19 : 666-675, 2001

14 Ghoneim MA, "Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases" 158 : 393-399, 1997

15 Quilty PM, "Primary radical radiotherapy for T3 transitional cell cancer of the bladder an analysis of survival and control" 853-860,

16 Shipley WU, "Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03" 16 : 3576-3583, 1998

17 Mills RD, "Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy" 166 : 19-23, 2001

18 Vieweg J, "Pelvic lymph node dissection can be curative in patients with node positive bladder cancer" 161 : 449-454, 1999

19 Shipley WU, "Overview of bladder cancer trials in the Radiation Therapy Oncology Group" 97 : 2115-2119, 2003

20 Zietman AL, "Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors" 170 : 1772-1776, 2003

21 Tester W, "Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802" 14 : 119-126, 1996

22 Moonen L, "Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment" 49 : 149-155, 1998

23 McDougal WS, "Metabolic complications of urinary intestinal diversion" 1199-1208, jurol1992;147

24 Sauer R, "Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer" 40 : 121-127, 1998

25 Dalbagni G, "Cystectomy for bladder cancer: a contemporary series" 165 : 1111-1116, 2001

26 Birkenhake S, "Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results" 175 : 97-101, 1999

27 Rodel C, "Combined- modality treatment and selective organ preservation in invasive bladder cancer: long-term results" 20 : 3061-3071, 2002

28 Yoon SM, "Combined modality therapy with selective bladder preservation for muscle invading bladder cancer" 19 : 237-244, 2001

29 Cho JH, "Bladder preservation by combined modality therapy for invasive bladder cancer: a five-year follow-up" 19 : 359-368, 2001

30 Mameghan H, "Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder" 31 : 247-254, 1995

31 Stockle M, "Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience" 153 : 47-52, 1995

32 Chahal R, "A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire" 43 : 246-257, 2003

33 Freiha F, "A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer" 155 : 495-499, 1996

34 Hayter CR, "A population-based study of the use and outcome of radical radiotherapy for invasive bladder cancer" 45 : 1239-1245, 1999